Transaction DateRecipientSharesTypePriceValue
20th October 2020Curet Myriam875Exercise of derivative$238.91$209,049.14
20th October 2020Curet Myriam875Open or private sale$736.12$644,105.00
14th October 2020Jeffrey Robert Ajer2,121Open or private sale$79.91$169,489.11
28th September 2020Jeffrey Robert Ajer3,250Open or private sale$17.25$56,062.50
25th September 2020Robert Chess5,500Open or private sale$17.75$97,625.00
22nd September 2020Roy A Whitfield9,100Grant/award etc.$0.00
22nd September 2020R Scott Greer9,100Grant/award etc.$0.00
22nd September 2020Jeffrey Robert Ajer9,100Grant/award etc.$0.00
22nd September 2020Curet Myriam9,100Grant/award etc.$0.00
22nd September 2020Robert Chess9,100Grant/award etc.$0.00
Nektar Therapeutics
Nektar Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Nektar Therapeutics is a biopharmaceutical company. It focuses on the therapies for cancer, autoimmune disease, and chronic pain. The company was founded in 1990 and is headquartered in San Francisco, CA.

Ticker: NKTR
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 906709
Employees: 723
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $58 M (0%)
Inventory, Net: $13 M (0%)
Other Assets, Current: $38 M (145%)
Assets, Current: $1 B (-18%)
Property, Plant and Equipment, Net: $61 M (-6%)
Other Assets, Noncurrent: $1 M (310%)
Assets: $2 B (-19%)
Accounts Payable, Current: $19 M (0%)
Liabilities, Current: $124 M (-64%)
Other Liabilities, Noncurrent: $2 M (191%)
Liabilities: $339 M (-40%)
Common Stock, Value, Issued: $18 Th (5%)
Additional Paid in Capital, Common Stock: $3 B (2%)
Retained Earnings (Accumulated Deficit): $2 B (11%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $715 Th (-28%)
Stockholders' Equity (Parent): $1 B (0%)
Liabilities and Equity: $2 B (-19%)
Revenue: $49 M (-50%)
Cost of Revenue: $6 M (-39%)
Research and Development: $96 M (-53%)
General and Administrative Expenses: $24 M (-51%)
Operating Income/Loss: $78 M (-63%)
Other Income, net: $2 M (-69%)
Provision for income taxes: $144 Th (-58%)